Early Alzheimer’s Disease: Developing Drugs for Treatment
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
March 12, 2024
March 12, 2024
ef0ff9a7-7208-4951-acbb-acb9937f83e7
Related Documents
Safety Labeling Changes—Implementation of Section 505(o)(4) of the FD&C Act: Draft Guidance for Industry
Guidance DocumentSeptember 18, 2025Center for Drug Evaluation and Research
Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials; Draft Guidance for Industry; Availability
Guidance DocumentOctober 31, 2022Center for Drug Evaluation and Research
Fabry Disease: Developing Drugs for Treatment Guidance for Industry
Guidance DocumentAugust 7, 2019Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox